|Generic name||Omacetaxine mepesuccinate|
|Brand name(s), other common name(s)||SynriboTM|
|How the drug is given||Subcutaneous (SC) injection|
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
Side effects needing medical attention:Low platelet counts, low red blood cell counts, low white blood cell counts, low level of lymphocytes, diarrhea, nausea, fatigue, weakness, injection site reaction, fever, infection, febrile neutropenia, constipation, vomiting, upper abdominal pain, peripheral edema, joint pain, pain in extremity, back pain, headache, insomnia, cough, nose bleed, hair loss, rash.